Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2019 | Pembro continues to demonstrate OS benefit in first-line NSCLC: KEYNOTE-024 update

Martin Reck, MD, PhD, of Hospital Grosshansdorf, Grosshansdorf, Germany, presents an updated overall survival (OS) and tolerability analysis from the Phase III KEYNOTE-024 trial (NCT02142738), which compared pembrolizumab monotherapy with standard chemotherapy in the frontline setting for advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression and without EGFR/ALK aberrations. Prof. Reck emphasizes how this longer follow-up showed that single-agent pembrolizumab continued to exhibit an OS benefit in this population. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland.